Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and safety of semaglutide once-weekly versus placebo in drug-naive subjects with type 2 diabetes

Trial Profile

Efficacy and safety of semaglutide once-weekly versus placebo in drug-naive subjects with type 2 diabetes

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Semaglutide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms SUSTAIN 1
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 11 Jun 2019 Post hoc analysis results from SUSTAIN 1-5 and 7 studies were presented at the 79th Annual Scientific Sessions of the American Diabetes Association.
    • 11 Jun 2019 Results of post hoc analysis assessing the proportion of semaglutide-treated subjects achieving clinically relevant responses by baseline HbA1c and body weight across SUSTAIN 1-5 and 7 trials presented at the 79th Annual Scientific Sessions of the American Diabetes Association
    • 02 Apr 2019 Results of post hoc analysis investigating the relationship between insulin resistance and body weight across the SUSTAIN 1-3 trials published in the Journal of Clinical Endocrinology and Metabolism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top